Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER‬‬‬

Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):101760. doi: 10.1016/j.clinre.2021.101760. Epub 2021 Jul 27.

Abstract

Background: More patient data are needed to improve research on rare liver diseases. Mobile health apps enable an exhaustive data collection. Therefore, the European Reference Network on Hepatological diseases (ERN RARE-LIVER) intends to implement an app for patients with rare liver diseases communicating with a patient registry, but little is known about which features patients and their healthcare providers regard as being useful.

Aims: This study aimed to investigate how an app for rare liver diseases would be accepted, and to find out which features are considered useful.

Methods: An anonymous survey was conducted on adult patients with rare liver diseases at a single academic, tertiary care outpatient-service. Additionally, medical experts of the ERN working group on autoimmune hepatitis were invited to participate in an online survey.

Results: In total, the responses from 100 patients with autoimmune (n = 90) or other rare (n = 10) liver diseases and 32 experts were analyzed. Patients were convinced to use a disease specific app (80%) and expected some benefit to their health (78%) but responses differed significantly between younger and older patients (93% vs. 62%, p < 0.001; 88% vs. 64%, p < 0.01). Comparing patients' and experts' feedback, patients more often expected a simplified healthcare pathway (e.g. 89% vs. 59% (p < 0.001) wanted access to one's own medical records), while healthcare providers saw the benefit mainly in improving compliance and treatment outcome (e.g. 93% vs. 31% (p < 0.001) and 70% vs. 21% (p < 0.001) expected the app to reduce mistakes in taking medication and improve quality of life, respectively).

Conclusion: Our results underline the great desire for disease-specific apps but also the need to involve patients and healthcare providers in the development of such apps in order to achieve long-term use and, thereby, improvements of patient care and research. The results of this study will help tremendously to implement the first cross-country app that communicates with an ERN patient registry.

Keywords: Autoimmune hepatitis; European reference networks; Mobile applications; Patient reported outcome measures; Primary biliary cholangitis; Primary sclerosing cholangitis.

MeSH terms

  • Adult
  • Humans
  • Liver Diseases* / therapy
  • Mobile Applications*
  • Rare Diseases* / therapy
  • Surveys and Questionnaires